Arkadios Wealth Advisors Acquires 3,650 Shares of Icon Plc $ICLR

Arkadios Wealth Advisors lifted its holdings in shares of Icon Plc (NASDAQ:ICLR) by 35.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,832 shares of the medical research company’s stock after buying an additional 3,650 shares during the quarter. Arkadios Wealth Advisors’ holdings in Icon were worth $2,421,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Artisan Partners Limited Partnership boosted its stake in Icon by 67.4% in the second quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock valued at $1,045,039,000 after acquiring an additional 2,893,946 shares during the last quarter. Harris Associates L P acquired a new position in shares of Icon in the 2nd quarter valued at $238,256,000. Norges Bank bought a new position in shares of Icon in the 2nd quarter worth $158,639,000. 1832 Asset Management L.P. boosted its position in shares of Icon by 587.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company’s stock worth $167,461,000 after purchasing an additional 983,950 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Icon during the second quarter worth $94,814,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Trading Up 1.0%

ICLR opened at $186.74 on Friday. The stock has a market capitalization of $15.08 billion, a P/E ratio of 25.27, a P/E/G ratio of 3.89 and a beta of 1.26. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 12 month low of $125.10 and a 12 month high of $211.00. The firm’s fifty day simple moving average is $180.89 and its 200 day simple moving average is $174.92.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ICLR shares. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Weiss Ratings restated a “hold (c)” rating on shares of Icon in a research report on Monday, December 29th. TD Cowen increased their price target on shares of Icon from $172.00 to $183.00 and gave the company a “hold” rating in a research report on Thursday. UBS Group set a $220.00 price objective on shares of Icon in a research note on Friday, October 24th. Finally, Bank of America cut shares of Icon from a “buy” rating to a “neutral” rating and set a $195.00 price objective for the company. in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, Icon currently has an average rating of “Hold” and an average target price of $200.60.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.